Also known as Rozerem
Ramelteon, marketed as Rozerem by Takeda Pharmaceuticals North America, is the first in a new class of sleep agents that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), instead of binding to GABA A receptors, such as with drugs like zolpidem, eszopiclone, and zaleplon. Ramelteon is approved by the U.S. Food and Drug Administration (FDA) for long-term use.Source: Wikipedia
Estimated Total Cost: $128.16 for an average of 28 days supply
Patients are most commonly prescribed ramelteon to treat depression, bipolar disorder, insomnia, and personality disorder.